Multicenter Clinical Study on the Safety and Efficacy of Nilotinib Discontinuation in Patients with Chronic Myelogenous Leukemia-Chronic Phase and Complete Molecular Response.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STAT2
- 25 Jun 2017 Results of association of nilotinib trough concentraion and liver dysfunction data from two studies (STAT1 and STAT2) presented at the 22nd Congress of the European Haematology Association
- 06 Dec 2016 Results of subgroup analysis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 27 Oct 2014 Planned End Date changed from 1 Jun 2015 to 7 Feb 2016 as reported by University Hospital Medical Information Network Japan.